A remarkable breakthrough in anti-aging research has been achieved with the discovery of a single molecule that has the potential to restore muscle strength, fuel brain cell growth, and reduce inflammation in older mice. While this anti-aging compound has only been tested in rodents and lab-grown human cells, the promising results have led researchers to consider moving towards human trials within the next few years.

Lead author of the study, Dr. Ronald DePinho, a professor and former president at The University of Texas MD Anderson Cancer Center, expressed confidence in the strength of the preclinical data and the potential beneficial effects of this mechanism on healthspan. The molecule targets the telomerase reverse transcriptase (TERT) protein, which plays a crucial role in maintaining the length of protective caps on chromosomes called telomeres. The shortening of telomeres has been linked to aging and age-related diseases.

The accumulation of chemical tags on chromosomes results in the suppression of TERT gene expression, leading to decreased telomere integrity and a wide range of effects on gene expression related to aging. However, the research team successfully reversed this process by restoring TERT levels in mice and observing rejuvenation in cells throughout their bodies.

The compound, called TERT-activating compound (TAC), was screened from a pool of 653,000 substances. The researchers discovered that TAC increased TERT levels in healthy human cells, as well as in cells derived from individuals with Werner syndrome, a condition characterized by rapid aging. In mice injected with TAC, the molecule effectively increased TERT levels throughout the body, including the brain.

In short-term treatments with TAC, the researchers observed the reversal of aging signs in blood cells, a decrease in senescence in various tissues, and an increase in a key molecule for brain cell growth. Long-term treatment led to increased brain cell growth in the hippocampus, an essential area for memory, and improved performance in memory tests. Additionally, the mice displayed enhanced coordination and muscle strength.

The mechanism of TAC involves activating a master gene regulator within cells, which in turn unmutes the TERT gene. However, the effects of the drug are temporary, peaking within approximately eight hours and wearing off after 24 hours. Despite this, TAC successfully restores youthful levels of TERT during this window.

Further studies are required to optimize the drug's potency and screen for potential harmful effects. Once these steps are completed, TAC or its derivatives will need to undergo additional animal testing before progressing to human trials. While the drug shows potential in preventing age-related diseases, it is likely to be initially approved for specific conditions such as Alzheimer's.

This groundbreaking research presents a promising pathway towards reversing the aging process and improving overall health in older individuals. As the preclinical data continues to impress, scientists and researchers eagerly anticipate the next stages of testing and the potential benefits this molecule could bring to human health.

For inquiries about the human body and its workings, readers are encouraged to send their questions to community@livescience.com with the subject line "Health Desk Q," and their questions may be answered on the website.